|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Liu C, Zhu S, Liang X, Zhang Q,
Luo X, Yuan L and Song L: PD-1/PD-L1 immune checkpoint
blockade-based combinational treatment: Immunotherapeutic
amplification strategies against colorectal cancer. Int
Immunopharmacol. 96:1076072021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020. View Article : Google Scholar
|
|
6
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng X, Xu X, Chen D, Zhao F and Wang W:
Therapeutic potential of targeting the Wnt/β-catenin signaling
pathway in colorectal cancer. Biomed Pharmacother. 110:473–481.
2019. View Article : Google Scholar
|
|
8
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/betacatenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar
|
|
9
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
11
|
Lee YH, Kung PT, Wang YH, Kuo WY, Kao SL
and Tsai WC: Effect of length of time from diagnosis to treatment
on colorectal cancer survival: A population-based study. PLoS One.
14:e02104652019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Banerjee A, Pathak S, Subramanium VD, G D,
Murugesan R and Verma RS: Strategies for targeted drug delivery in
treatment of colon cancer: Current trends and future perspectives.
Drug Discov Today. 22:1224–1232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Payandeh Z, Khalili S, Somi MH,
Mard-Soltani M, Baghbanzadeh A, Hajiasgharzadeh K, Samadi N and
Baradaran B: PD-1/PD-L1-dependent immune response in colorectal
cancer. J Cell Physiol. 235:5461–5475. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao Y and Freeman GJ: The microsatellite
instable subset of colorectal cancer is a particularly good
candidate for checkpoint blockade immunotherapy. Cancer Discov.
5:16–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Silva VR, Santos LS, Dias RB, Quadros CA
and Bezerra DP: Emerging agents that target signaling pathways to
eradicate colorectal cancer stem cells. Cancer Commun (Lond).
41:1275–1313. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang
J, Zhang G, Wang X, Dong Z, Chen F and Cui H: Targeting cancer stem
cell pathways for cancer therapy. Signal Transduct Target Ther.
5:82020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Voorneveld PW, Kodach LL, Jacobs RJ, van
Noesel CJ, Peppelenbosch MP, Korkmaz KS, Molendijk I, Dekker E,
Morreau H, van Pelt GW, et al: The BMP pathway either enhances or
inhibits the Wnt pathway depending on the SMAD4 and p53 status in
CRC. Br J Cancer. 112:122–130. 2015. View Article : Google Scholar :
|
|
20
|
Nusse R and Clevers H: Wnt/β-Catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duchartre Y, Kim YM and Kahn M: The Wnt
signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taciak B, Pruszynska I, Kiraga L, Bialasek
M and Krol M: Wnt signaling pathway in development and cancer. J
Physiol Pharmacol. 69:Jul 4–2018.Epub ahead of print. PubMed/NCBI
|
|
23
|
Wang D, Zhang Q, Li F, Wang C, Yang C and
Yu H: β-TrCP-mediated ubiquitination and degradation of Dlg5
regulates hepatocellular carcinoma cell proliferation. Cancer Cell
Int. 19:2982019. View Article : Google Scholar
|
|
24
|
DeBruine ZJ, Xu HE and Melcher K: Assembly
and architecture of the Wnt/β-catenin signalosome at the membrane.
Br J Pharmacol. 174:4564–4574. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qi J, Lee HJ, Saquet A, Cheng XN, Shao M,
Zheng JJ and Shi DL: Autoinhibition of Dishevelled protein
regulated by its extreme C terminus plays a distinct role in
Wnt/β-catenin and Wnt/planar cell polarity (PCP) signaling
pathways. J Biol Chem. 292:5898–5908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schatoff EM, Leach BI and Dow LE: Wnt
signaling and colorectal cancer. Curr Colorectal Cancer Rep.
13:101–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gómez-Orte E, Sáenz-Narciso B, Moreno S
and Cabello J: Multiple functions of the noncanonical Wnt pathway.
Trends Genet. 29:545–553. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De A: Wnt/Ca2+ signaling pathway: A brief
overview. Acta Biochim Biophys Sin (Shanghai). 43:745–756. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chae WJ and Bothwell ALM: Canonical and
Non-Canonical Wnt signaling in immune cells. Trends Immunol.
39:830–847. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Es JH, Haegebarth A, Kujala P,
Itzkovitz S, Koo BK, Boj SF, Korving J, van den Born M, van
Oudenaarden A, Robine S and Clevers H: A critical role for the Wnt
effector Tcf4 in adult intestinal homeostatic self-renewal. Mol
Cell Biol. 32:1918–1927. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato T, Vries RG, Snippert HJ, van de
Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters
PJ and Clevers H: Single Lgr5 stem cells build crypt-villus
structures in vitro without a mesenchymal niche. Nature.
459:262–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Farin HF, Jordens I, Mosa MH, Basak O,
Korving J, Tauriello DV, de Punder K, Angers S, Peters PJ, Maurice
MM and Clevers H: Visualization of a short-range Wnt gradient in
the intestinal stem-cell niche. Nature. 530:340–343. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen M, Lin W, Li N, Wang Q, Zhu S, Zeng A
and Song L: Therapeutic approaches to colorectal cancer via
strategies based on modulation of gut microbiota. Front Microbiol.
13:9455332022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shoshkes-Carmel M, Wang YJ, Wangensteen
KJ, Tóth B, Kondo A, Massasa EE, Itzkovitz S and Kaestner KH:
Subepithelial telocytes are an important source of Wnts that
supports intestinal crypts. Nature. 557:242–246. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kahn M: Wnt signaling in stem cells and
cancer stem cells: A tale of two coactivators. Prog Mol Biol Transl
Sci. 153:209–244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aceto GM, Catalano T and Curia MC:
Molecular aspects of colorectal adenomas: The interplay among
microenvironment, oxidative stress, and predisposition. Biomed Res
Int. 2020:17263092020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bright-Thomas RM and Hargest R: APC,
beta-Catenin and hTCF-4; an unholy trinity in the genesis of
colorectal cancer. Eur J Surg Oncol. 29:107–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang L and Shay JW: Multiple roles of APC
and its therapeutic implications in colorectal cancer. J Natl
Cancer Inst. 109:djw3322017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q
and Zhang J: Upregulated miR-130a increases drug resistance by
regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
Biochem Biophys Res Commun. 425:468–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen DY, Zhang W, Zeng X and Liu CQ:
Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein
and reverses multi-drug resistance of cholangiocarcinoma. Cancer
Sci. 104:1303–1308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Krausova M and Korinek V: Wnt signaling in
adult intestinal stem cells and cancer. Cell Signal. 26:570–579.
2014. View Article : Google Scholar
|
|
42
|
Roy S and Majumdar AP: Signaling in colon
cancer stem cells. J Mol Signal. 7:112012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sebio A, Kahn M and Lenz HJ: The potential
of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther
Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tai D, Wells K, Arcaroli J, Vanderbilt C,
Aisner DL, Messersmith WA and Lieu CH: Targeting the WNT signaling
pathway in cancer therapeutics. Oncologist. 20:1189–1198. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Paluszczak J, Kleszcz R, Studzińska-Sroka
E and Krajka-Kuźniak V: Lichen-derived caperatic acid and physodic
acid inhibit Wnt signaling in colorectal cancer cells. Mol Cell
Biochem. 441:109–124. 2018. View Article : Google Scholar :
|
|
46
|
Gekas C, D'Altri T, Aligué R, González J,
Espinosa L and Bigas A: β-Catenin is required for T-cell leukemia
initiation and MYC transcription downstream of Notch1. Leukemia.
30:2002–2010. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li L, Peng W, Zhou Q, Wan JP, Wang XT and
Qi HB: LRP6 regulates Rab7-mediated autophagy through the
Wnt/β-catenin pathway to modulate trophoblast cell migration and
invasion. J Cell Biochem. 121:1599–1609. 2020. View Article : Google Scholar
|
|
48
|
Matsuzaki S and Darcha C: Involvement of
the Wnt/β-catenin signaling pathway in the cellular and molecular
mechanisms of fibrosis in endometriosis. PLoS One. 8:e768082013.
View Article : Google Scholar
|
|
49
|
Kim JY, Park G, Krishnan M, Ha E and Chun
KS: Selective Wnt/β-catenin Small-molecule Inhibitor CWP232228
impairs tumor growth of colon cancer. Anticancer Res. 39:3661–3667.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ,
Lee ES, Park JH, Yun CH, Chung JU, Lee KJ, et al: Wnt/β-Catenin
small-molecule inhibitor CWP232228 preferentially inhibits the
growth of breast cancer stem-like cells. Cancer Res. 75:1691–1702.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim JY, Lee HY, Park KK, Choi YK, Nam JS
and Hong IS: CWP232228 targets liver cancer stem cells through
Wnt/β-catenin signaling: A novel therapeutic approach for liver
cancer treatment. Oncotarget. 7:20395–20409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kazi A, Xiang S, Yang H, Delitto D,
Trevino J, Jiang RHY, Ayaz M, Lawrence HR, Kennedy P and Sebti SM:
GSK3 suppression upregulates β-catenin and c-Myc to abrogate
KRas-dependent tumors. Nat Commun. 9:51542018. View Article : Google Scholar
|
|
53
|
Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian
Y, Li W, Chen H, Gou H, Liu D, et al: In colorectal cancer cells
with mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA
demethylation to increase WNT signaling, stemness, and drug
resistance. Gastroenterology. 159:2163–2180.e6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Du F, Cao T, Xie H, Li T, Sun L, Liu H,
Guo H, Wang X, Liu Q, Kim T, et al: KRAS Mutation-Responsive
miR-139-5p inhibits colorectal cancer progression and is repressed
by Wnt signaling. Theranostics. 10:7335–7350. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mologni L, Brussolo S, Ceccon M and
Gambacorti-Passerini C: Synergistic effects of combined Wnt/KRAS
inhibition in colorectal cancer cells. PLoS One. 7:e514492012.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen Z, Venkatesan AM, Dehnhardt CM, Dos
Santos O, Delos Santos E, Ayral-Kaloustian S, Chen L, Geng Y, Arndt
KT, Lucas J, et al: 2,4-Diamino-quinazolines as inhibitors of
beta-catenin/Tcf-4 pathway: Potential treatment for colorectal
cancer. Bioorg Med Chem Lett. 19:4980–4983. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dehnhardt CM, Venkatesan AM, Chen Z,
Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K,
Follettie MT, Diesl V, Lucas J, et al: Design and synthesis of
novel diaminoquinazolines with in vivo efficacy for
beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J
Med Chem. 53:897–910. 2010. View Article : Google Scholar
|
|
58
|
Chang TS, Lu CK, Hsieh YY, Wei KL, Chen
WM, Tung SY, Wu CS, Chan MWY and Chiang MK:
2,4-Diamino-Quinazoline, a Wnt signaling inhibitor, suppresses
gastric cancer progression and metastasis. Int J Mol Sci.
21:59012020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fan HC, Hsieh YC, Li LH and Chang CC,
Janoušková K, Ramani MV, Subbaraju GV, Cheng KT and Chang CC:
Dehydroxyhispolon methyl ether, a hispolon derivative, inhibits
WNT/β-Catenin signaling to elicit human colorectal carcinoma cell
apoptosis. Int J Mol Sci. 21:88392020. View Article : Google Scholar
|
|
60
|
Wu L, Zhou Z, Han S, Chen J, Liu Z, Zhang
X, Yuan W, Ji J and Shu X: PLAGL2 promotes epithelial-mesenchymal
transition and mediates colorectal cancer metastasis via
β-catenin-dependent regulation of ZEB1. Br J Cancer. 122:578–589.
2020. View Article : Google Scholar
|
|
61
|
Low JL, Du W, Gocha T, Oguz G, Zhang X,
Chen MW, Masirevic S, Yim DGR, Tan IBH, Ramasamy A, et al:
Molecular docking-aided identification of small molecule inhibitors
targeting β-catenin-TCF4 interaction. iScience. 24:1025442021.
View Article : Google Scholar
|
|
62
|
Hu J, Wang Z, Chen J, Yu Z, Zhang J, Li W,
Lin M, Yang X and Liu H: Overexpression of ICAT inhibits the
progression of colorectal cancer by binding with β-Catenin in the
cytoplasm. Technol Cancer Res Treat. 20:153303382110412532021.
View Article : Google Scholar
|
|
63
|
Masuda M, Uno Y, Ohbayashi N, Ohata H,
Mimata A, Kukimoto-Niino M, Moriyama H and Kashimoto S: TNIK
inhibition abrogates colorectal cancer stemness. Nat Commun.
7:125862016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yamada T and Masuda M: Emergence of TNIK
inhibitors in cancer therapeutics. Cancer Sci. 108:818–823. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sugano T, Masuda M, Takeshita F, Motoi N,
Hirozane T, Goto N, Kashimoto S, Uno Y, Moriyama H, Sawa M, et al:
Pharmacological blockage of transforming growth factor-β signalling
by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. Br J
Cancer. 124:228–236. 2021. View Article : Google Scholar
|
|
66
|
Sekita T, Yamada T, Kobayashi E, Yoshida
A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, et
al: Feasibility of targeting Traf2-and-Nck-Interacting kinase in
synovial sarcoma. Cancers (Basel). 12:12582020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jung HR, Oh Y, Na D, Min S, Kang J, Jang
D, Shin S, Kim J, Lee SE, Jeong EM, et al: CRISPR screens identify
a novel combination treatment targeting BCL-XL and WNT
signaling for KRAS/BRAF-mutated colorectal cancers. Oncogene.
40:3287–3302. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhao L, Sun L, Lu Y, Li F and Xu H: A
small-molecule LF3 abrogates β-catenin/TCF4-mediated suppression of
NaV 1.5 expression in HL-1 cardiomyocytes. J Mol Cell
Cardiol. 135:90–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Fang L, Zhu Q, Neuenschwander M, Specker
E, Wulf-Goldenberg A, Weis WI, von Kries JP and Birchmeier W: A
small-molecule antagonist of the β-Catenin/TCF4 interaction blocks
the self-renewal of cancer stem cells and suppresses tumorigenesis.
Cancer Res. 76:891–901. 2016. View Article : Google Scholar
|
|
70
|
Gurpinar E, Grizzle WE and Piazza GA:
NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res.
20:1104–1113. 2014. View Article : Google Scholar :
|
|
71
|
Sareddy GR, Kesanakurti D, Kirti PB and
Babu PP: Nonsteroidal anti-inflammatory drugs diclofenac and
celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human
glioblastoma cells. Neurochem Res. 38:2313–2322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li N, Xi Y, Tinsley HN, Gurpinar E, Gary
BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH, et al: Sulindac
selectively inhibits colon tumor cell growth by activating the
cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer
Ther. 12:1848–1859. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Egashira I, Takahashi-Yanaga F, Nishida R,
Arioka M, Igawa K, Tomooka K, Nakatsu Y, Tsuzuki T, Nakabeppu Y,
Kitazono T and Sasaguri T: Celecoxib and 2,5-dimethylcelecoxib
inhibit intestinal cancer growth by suppressing the Wnt/β-catenin
signaling pathway. Cancer Sci. 108:108–115. 2017. View Article : Google Scholar
|
|
74
|
Bowen CM, Walter L, Borras E, Wu W, Ozcan
Z, Chang K, Bommi PV, Taggart MW, Thirumurthi S, Lynch PM, et al:
Combination of sulindac and bexarotene for prevention of intestinal
carcinogenesis in familial adenomatous polyposis. Cancer Prev Res
(Phila). 14:851–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wu M, Guan J, Li C, Gunter S, Nusrat L, Ng
S, Dhand K, Morshead C, Kim A and Das S: Aberrantly activated Cox-2
and Wnt signaling interact to maintain cancer stem cells in
glioblastoma. Oncotarget. 8:82217–82230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bindu S, Mazumder S and Bandyopadhyay U:
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A
current perspective. Biochem Pharmacol. 180:1141472020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Grosser T, Ricciotti E and FitzGerald GA:
The cardiovascular pharmacology of nonsteroidal anti-inflammatory
drugs. Trends Pharmacol Sci. 38:733–748. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Walker C and Biasucci LM: Cardiovascular
safety of non-steroidal anti-inflammatory drugs revisited. Postgrad
Med. 130:55–71. 2018. View Article : Google Scholar
|
|
79
|
Yan KS, Janda CY, Chang J, Zheng GXY,
Larkin KA, Luca VC, Chia LA, Mah AT, Han A, Terry JM, et al:
Non-equivalence of Wnt and R-spondin ligands during
Lgr5+ intestinal stem-cell self-renewal. Nature.
545:238–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gurney A, Axelrod F, Bond CJ, Cain J,
Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, et
al: Wnt pathway inhibition via the targeting of Frizzled receptors
results in decreased growth and tumorigenicity of human tumors.
Proc Natl Acad Sci USA. 109:11717–11722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang Y, Morris JP IV, Yan W, Schofield
HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M and Pasca di
Magliano M: Canonical wnt signaling is required for pancreatic
carcinogenesis. Cancer Res. 73:4909–4922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Flanagan DJ, Barker N, Costanzo NSD, Mason
EA, Gurney A, Meniel VS, Koushyar S, Austin CR, Ernst M, Pearson
HB, et al: Frizzled-7 is required for Wnt signaling in gastric
tumors with and without apc mutations. Cancer Res. 79:970–981.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Diamond JR, Becerra C, Richards D, Mita A,
Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, et
al: Phase Ib clinical trial of the anti-frizzled antibody
vantictumab (OMP-18R5) plus paclitaxel in patients with locally
advanced or metastatic HER2-negative breast cancer. Breast Cancer
Res Treat. 184:53–62. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Le PN, McDermott JD and Jimeno A:
Targeting the Wnt pathway in human cancers: Therapeutic targeting
with a focus on OMP-54F28. Pharmacol Ther. 146:1–11. 2015.
View Article : Google Scholar
|
|
85
|
Jimeno A, Gordon M, Chugh R, Messersmith
W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S,
et al: A First-in-human phase I study of the anticancer stem cell
agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in
patients with advanced solid tumors. Clin Cancer Res. 23:7490–7497.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Dotan E, Cardin DB, Lenz HJ, Messersmith
W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun
AM, et al: Phase Ib study of wnt inhibitor ipafricept with
gemcitabine and nab-paclitaxel in patients with previously
untreated stage IV pancreatic cancer. Clin Cancer Res.
26:5348–5357. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Moore KN, Gunderson CC, Sabbatini P,
McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM,
Brachmann RK, Stagg R, et al: A phase 1b dose escalation study of
ipafricept (OMP54F28) in combination with paclitaxel and
carboplatin in patients with recurrent platinum-sensitive ovarian
cancer. Gynecol Oncol. 154:294–301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Le PN, Keysar SB, Miller B, Eagles JR,
Chimed TS, Reisinger J, Gomez KE, Nieto C, Jackson BC, Somerset HL,
et al: Wnt signaling dynamics in head and neck squamous cell cancer
tumor-stroma interactions. Mol Carcinog. 58:398–410. 2019.
View Article : Google Scholar :
|
|
89
|
Madan B, McDonald MJ, Foxa GE, Diegel CR,
Williams BO and Virshup DM: Bone loss from Wnt inhibition mitigated
by concurrent alendronate therapy. Bone Res. 6:172018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Resh MD: Palmitoylation of ligands,
receptors, and intracellular signaling molecules. Sci STKE.
2006:re142006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Torres VI, Godoy JA and Inestrosa NC:
Modulating Wnt signaling at the root: Porcupine and Wnt acylation.
Pharmacol Ther. 198:34–45. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Nile AH and Hannoush RN: Fatty acylation
of Wnt proteins. Nat Chem Biol. 12:60–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Bagheri M, Tabatabae Far MA, Mirzaei H and
Ghasemi F: Evaluation of antitumor effects of aspirin and LGK974
drugs on cellular signaling pathways, cell cycle and apoptosis in
colorectal cancer cell lines compared to oxaliplatin drug. Fundam
Clin Pharmacol. 34:51–64. 2020. View Article : Google Scholar
|
|
94
|
Hayashi M, Baker A, Goldstein SD, Albert
CM, Jackson KW, McCarty G, Kahlert UD and Loeb DM: Inhibition of
porcupine prolongs metastasis free survival in a mouse xenograft
model of Ewing sarcoma. Oncotarget. 8:78265–78276. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Rudy SF, Brenner JC, Harris JL, Liu J, Che
J, Scott MV, Owen JH, Komarck CM, Graham MP, Bellile EL, et al: In
vivo Wnt pathway inhibition of human squamous cell carcinoma growth
and metastasis in the chick chorioallantoic model. J Otolaryngol
Head Neck Surg. 45:262016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang
T, Kasibhatla S, Schuller AG, Li AG, Cheng D, et al: Targeting
Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Proc Natl Acad Sci USA. 110:20224–20229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Li J, Wu G, Xu Y, Li J, Ruan N, Chen Y,
Zhang Q and Xia Q: Porcupine Inhibitor LGK974 Downregulates the Wnt
signaling pathway and inhibits clear cell renal cell carcinoma.
Biomed Res Int. 2020:25276432020.PubMed/NCBI
|
|
98
|
Cho YH, Ro EJ, Yoon JS, Mizutani T, Kang
DW, Park JC, Il Kim T, Clevers H and Choi KY: 5-FU promotes
stemness of colorectal cancer via p53-mediated WNT/β-catenin
pathway activation. Nat Commun. 11:53212020. View Article : Google Scholar
|
|
99
|
Guimaraes PPG, Tan M, Tammela T, Wu K,
Chung A, Oberli M, Wang K, Spektor R, Riley RS, Viana CTR, et al:
Potent in vivo lung cancer Wnt signaling inhibition via
cyclodextrin-LGK974 inclusion complexes. J Control Release.
290:75–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Jin XF, Spoettl G, Maurer J, Nölting S and
Auernhammer CJ: Inhibition of Wnt/β-Catenin signaling in
neuroendocrine tumors in vitro: Antitumoral effects. Cancers
(Basel). 12:3452020. View Article : Google Scholar
|
|
101
|
Suwala AK, Koch K, Rios DH, Aretz P,
Uhlmann C, Ogorek I, Felsberg J, Reifenberger G, Köhrer K, Deenen
R, et al: Inhibition of Wnt/beta-catenin signaling downregulates
expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to
reduce resistance against temozolomide in glioblastoma in vitro.
Oncotarget. 9:22703–22716. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Boone JD, Arend RC, Johnston BE, Cooper
SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade
A, Straughn JM Jr and Buchsbaum DJ: Targeting the Wnt/β-catenin
pathway in primary ovarian cancer with the porcupine inhibitor
WNT974. Lab Invest. 96:249–259. 2016. View Article : Google Scholar
|
|
103
|
Bland T, Wang J, Yin L, Pu T, Li J, Gao J,
Lin TP, Gao AC and Wu BJ: WLS-Wnt signaling promotes neuroendocrine
prostate cancer. iScience. 24:1019702021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Jiang X, Hao HX, Growney JD, Woolfenden S,
Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, et al:
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic
ductal adenocarcinoma. Proc Natl Acad Sci USA. 110:12649–12654.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li Y, Li J, Wang R, Zhang L, Fu G, Wang X,
Wang Y, Fang C, Zhang D, Du D, et al: Frequent RNF43 mutation
contributes to moderate activation of Wnt signaling in colorectal
signet-ring cell carcinoma. Protein Cell. 11:292–298. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Rodon J, Argilés G, Connolly RM,
Vaishampayan U, de Jonge M, Garralda E, Giannakis M, Smith DC,
Dobson JR, McLaughlin ME, et al: Phase 1 study of single-agent
WNT974, a first-in-class Porcupine inhibitor, in patients with
advanced solid tumours. Br J Cancer. 125:28–37. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mo ML, Li MR, Chen Z, Liu XW, Sheng Q and
Zhou HM: Inhibition of the Wnt palmitoyltransferase porcupine
suppresses cell growth and downregulates the Wnt/β-catenin pathway
in gastric cancer. Oncol Lett. 5:1719–1723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Blyszczuk P, Müller-Edenborn B, Valenta T,
Osto E, Stellato M, Behnke S, Glatz K, Basler K, Lüscher TF,
Distler O, et al: Transforming growth factor-β-dependent Wnt
secretion controls myofibroblast formation and myocardial fibrosis
progression in experimental autoimmune myocarditis. Eur Heart J.
38:1413–1425. 2017.
|
|
109
|
Najdi R, Proffitt K, Sprowl S, Kaur S, Yu
J, Covey TM, Virshup DM and Waterman ML: A uniform human Wnt
expression library reveals a shared secretory pathway and unique
signaling activities. Differentiation. 84:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Boulter L, Guest RV, Kendall TJ, Wilson
DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N,
Barry ST, et al: WNT signaling drives cholangiocarcinoma growth and
can be pharmacologically inhibited. J Clin Invest. 125:1269–1285.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Katoh M: Multi-layered prevention and
treatment of chronic inflammation, organ fibrosis and cancer
associated with canonical WNT/β-catenin signaling activation
(Review). Int J Mol Med. 42:713–725. 2018.PubMed/NCBI
|
|
112
|
Zhang J, Cai H, Sun L, Zhan P, Chen M,
Zhang F, Ran Y and Wan J: LGR5, a novel functional glioma stem cell
marker, promotes EMT by activating the Wnt/β-catenin pathway and
predicts poor survival of glioma patients. J Exp Clin Cancer Res.
37:2252018. View Article : Google Scholar
|
|
113
|
Jang J, Song J, Sim I, Kwon YV and Yoon Y:
Wnt-Signaling Inhibitor Wnt-C59 suppresses the cytokine
upregulation in multiple organs of lipopolysaccharide-induced
endotoxemic mice via reducing the interaction between β-Catenin and
NF-κB. Int J Mol Sci. 22:62492021. View Article : Google Scholar
|
|
114
|
Jang J, Song J, Sim I and Yoon Y: Wnt-C59
inhibits proinflammatory cytokine expression by reducing the
interaction between β-catenin and NF-κB in LPS-stimulated
epithelial and macrophage cells. Korean J Physiol Pharmacol.
25:307–319. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Madan B, Ke Z, Harmston N, Ho SY, Frois
AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH, et al:
Wnt addiction of genetically defined cancers reversed by PORCN
inhibition. Oncogene. 35:2197–2207. 2016. View Article : Google Scholar
|
|
116
|
Zhong Z, Sepramaniam S, Chew XH, Wood K,
Lee MA, Madan B and Virshup DM: PORCN inhibition synergizes with
PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene.
38:6662–6677. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Kaur A, Lim JYS, Sepramaniam S, Patnaik S,
Harmston N, Lee MA, Petretto E, Virshup DM and Madan B: WNT
inhibition creates a BRCA-like state in Wnt-addicted cancer. EMBO
Mol Med. 13:e133492021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Shirai F, Mizutani A, Yashiroda Y, Tsumura
T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, et al:
Design and discovery of an orally efficacious spiroindolinone-based
tankyrase inhibitor for the treatment of colon cancer. J Med Chem.
63:4183–4204. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kulak O, Chen H, Holohan B, Wu X, He H,
Borek D, Otwinowski Z, Yamaguchi K, Garofalo LA, Ma Z, et al:
Disruption of Wnt/β-Catenin signaling and telomeric shortening are
inextricable consequences of tankyrase inhibition in human cells.
Mol Cell Biol. 35:2425–2435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Arqués O, Chicote I, Puig I, Tenbaum SP,
Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J,
Silberschmidt D, et al: Tankyrase Inhibition Blocks Wnt/β-Catenin
pathway and reverts resistance to PI3K and AKT inhibitors in the
treatment of colorectal cancer. Clin Cancer Res. 22:644–656. 2016.
View Article : Google Scholar
|
|
121
|
Wu X, Luo F, Li J, Zhong X and Liu K:
Tankyrase1 inhibitior XAV939 increases chemosensitivity in colon
cancer cell lines via inhibition of the Wnt signaling pathway. Int
J Oncol. 48:1333–1340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Yu J, Liu D, Sun X, Yang K, Yao J, Cheng
C, Wang C and Zheng J: CDX2 inhibits the proliferation and tumor
formation of colon cancer cells by suppressing Wnt/β-catenin
signaling via transactivation of GSK-3β and Axin2 expression. Cell
Death Dis. 10:262019. View Article : Google Scholar
|
|
123
|
Sun K, He SB, Yao YZ, Qu JG, Xie R, Ma YQ,
Zong MH and Chen JX: Tre2 (USP6NL) promotes colorectal cancer cell
proliferation via Wnt/β-catenin pathway. Cancer Cell Int.
19:1022019. View Article : Google Scholar
|
|
124
|
Alula KM, Delgado-Deida Y, Jackson DN,
Venuprasad K and Theiss AL: Nuclear partitioning of Prohibitin 1
inhibits Wnt/β-catenin-dependent intestinal tumorigenesis.
Oncogene. 40:369–383. 2021. View Article : Google Scholar
|
|
125
|
Wang T, Ning K, Lu TX and Hua D: Elevated
expression of TrpC5 and GLUT1 is associated with chemoresistance in
colorectal cancer. Oncol Rep. 37:1059–1065. 2017. View Article : Google Scholar
|
|
126
|
Xu J, Lv G, Xu B and Jiang B:
Overexpression of UBE2M through Wnt/β-Catenin signaling is
associated with poor prognosis and chemotherapy resistance in
colorectal cancer. Transl Cancer Res. 9:5614–5625. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Siraj AK, Kumar Parvathareddy S,
Pratheeshkumar P, Padmaja Divya S, Ahmed SO, Melosantos R, Begum R,
Concepcion RMJA, Al-Sanea N, Ashari LH, et al: APC truncating
mutations in Middle Eastern Population: Tankyrase inhibitor is an
effective strategy to sensitize APC mutant CRC To 5-FU
chemotherapy. Biomed Pharmacother. 121:1095722020. View Article : Google Scholar
|
|
128
|
Martins-Neves SR, Paiva-Oliveira DI,
Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM and Gomes CMF:
IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in
cancer stem-like cells and inhibits in vivo the growth of a
subcutaneous human osteosarcoma xenograft. Cancer Lett. 414:1–15.
2018. View Article : Google Scholar
|
|
129
|
Cheng C, Huang Z, Zhou R, An H, Cao G, Ye
J, Huang C and Wu D: Numb negatively regulates the
epithelial-to-mesenchymal transition in colorectal cancer through
the Wnt signaling pathway. Am J Physiol Gastrointest Liver Physiol.
318:G841–G853. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Okunlola FO, Akawa OB, Subair TI, Omolabi
KF and Soliman MES: Unravelling the mechanistic role of
quinazolinone pharmacophore in the inhibitory activity of
bis-quinazolinone derivative on tankyrase-1 in the treatment of
colorectal cancer (CRC) and non-small cell lung cancer (NSCLC): A
computational approach. Cell Biochem Biophys. 80:1–10. 2022.
View Article : Google Scholar
|
|
131
|
Lau T, Chan E, Callow M, Waaler J, Boggs
J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, et
al: A novel tankyrase small-molecule inhibitor suppresses APC
mutation-driven colorectal tumor growth. Cancer Res. 73:3132–3144.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Katoh M: Canonical and non-canonical WNT
signaling in cancer stem cells and their niches: Cellular
heterogeneity, omics reprogramming, targeted therapy and tumor
plasticity (Review). Int J Oncol. 51:1357–1369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Norum JH, Skarpen E, Brech A, Kuiper R,
Waaler J, Krauss S and Sørlie T: The tankyrase inhibitor G007-LK
inhibits small intestine LGR5+ stem cell proliferation
without altering tissue morphology. Biol Res. 51:32018. View Article : Google Scholar
|
|
134
|
Kierulf-Vieira KS, Sandberg CJ, Waaler J,
Lund K, Skaga E, Saberniak BM, Panagopoulos I, Brandal P, Krauss S,
Langmoen IA and Vik-Mo EO: A small-molecule tankyrase inhibitor
reduces glioma stem cell proliferation and sphere formation.
Cancers (Basel). 12:16302020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Waaler J, Mygland L, Tveita A, Strand MF,
Solberg NT, Olsen PA, Aizenshtadt A, Fauskanger M, Lund K, Brinch
SA, et al: Tankyrase inhibition sensitizes melanoma to PD-1 immune
checkpoint blockade in syngeneic mouse models. Commun Biol.
3:1962020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Solberg NT, Waaler J, Lund K, Mygland L,
Olsen PA and Krauss S: TANKYRASE inhibition enhances the
antiproliferative effect of PI3K and EGFR inhibition, mutually
affecting β-CATENIN and AKT signaling in colorectal cancer. Mol
Cancer Res. 16:543–553. 2018. View Article : Google Scholar
|
|
137
|
Tang L, Zhu H, Yang X, Xie F, Peng J,
Jiang D, Xie J, Qi M and Yu L: Shizukaol D, a dimeric sesquiterpene
isolated from chloranthus serratus, represses the growth of human
liver cancer cells by modulating wnt signalling pathway. PLoS One.
11:e01520122016. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Pricci M, Girardi B, Giorgio F, Losurdo G,
Ierardi E and Di Leo A: Curcumin and colorectal cancer: From basic
to clinical evidences. Int J Mol Sci. 21:23642020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Weng W and Goel A: Curcumin and colorectal
cancer: An update and current perspective on this natural medicine.
Semin Cancer Biol. 80:73–86. 2022. View Article : Google Scholar
|
|
140
|
Villegas C, Perez R, Sterner O,
González-Chavarría I and Paz C: Curcuma as an adjuvant in
colorectal cancer treatment. Life Sci. 286:1200432021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Jiang X, Li S, Qiu X, Cong J, Zhou J and
Miu W: Curcumin inhibits cell viability and increases apoptosis of
SW620 human colon adenocarcinoma cells via the caudal type
homeobox-2 (CDX2)/Wnt/β-catenin pathway. Med Sci Monit.
25:7451–7458. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Bian Y, Wang G, Zhou J, Yin G, Liu T,
Liang L, Liang L, Yang X, Zhang W, Ni K, et al: Astragalus
membranaceus (Huangqi) and Rhizoma curcumae (Ezhu) decoction
suppresses colorectal cancer via downregulation of Wnt5/β-Catenin
signal. Chin Med. 17:112022. View Article : Google Scholar
|
|
143
|
Wu X, Yu N, Zhang Y, Ye Y, Sun W, Ye L, Wu
H, Yang Z, Wu L and Wang F: Radix Tetrastigma hemsleyani flavone
exhibits antitumor activity in colorectal cancer via Wnt/β-catenin
signaling pathway. Onco Targets Ther. 11:6437–6446. 2018.
View Article : Google Scholar :
|
|
144
|
Pintova S, Dharmupari S, Moshier E,
Zubizarreta N, Ang C and Holcombe RF: Genistein combined with
FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic
colorectal cancer: Phase I/II pilot study. Cancer Chemother
Pharmacol. 84:591–598. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Křížová L, Dadáková K, Kašparovská J and
Kašparovský T: Isoflavones. Molecules. 24:10762019. View Article : Google Scholar :
|
|
146
|
Dou R, Ng K, Giovannucci EL, Manson JE,
Qian ZR and Ogino S: Vitamin D and colorectal cancer: Molecular,
epidemiological and clinical evidence. Br J Nutr. 115:1643–1660.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Wesselink E, Kok DE, Bours MJL, de Wilt
JHW, van Baar H, van Zutphen M, Geijsen AMJR, Keulen ETP, Hansson
BME, van den Ouweland J, et al: Vitamin D, magnesium, calcium, and
their interaction in relation to colorectal cancer recurrence and
all-cause mortality. Am J Clin Nutr. 111:1007–1017. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kim H, Lipsyc-Sharf M, Zong X, Wang X, Hur
J, Song M, Wang M, Smith-Warner SA, Fuchs C, Ogino S, et al: Total
Vitamin D intake and risks of early-onset colorectal cancer and
precursors. Gastroenterology 2021. 161:1208–1217.e9. 2021.
|
|
149
|
Fernández-Barral A, Costales-Carrera A,
Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid
P, Domínguez O, Real FX, Guerra-Pastriá L, et al: Vitamin D
differentially regulates colon stem cells in patient-derived normal
and tumor organoids. FEBS J. 287:53–72. 2020. View Article : Google Scholar
|
|
150
|
Razak S, Afsar T, Almajwal A, Alam I and
Jahan S: Growth inhibition and apoptosis in colorectal cancer cells
induced by Vitamin D-Nanoemulsion (NVD): Involvement of
Wnt/β-catenin and other signal transduction pathways. Cell Biosci.
9:152019. View Article : Google Scholar
|
|
151
|
Ren H, Zhao J, Fan D, Wang Z, Zhao T, Li
Y, Zhao Y, Adelson D and Hao H: Alkaloids from nux vomica
suppresses colon cancer cell growth through Wnt/β-catenin signaling
pathway. Phytother Res. 33:1570–1578. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Seshadri VD: Brucine promotes apoptosis in
cervical cancer cells (ME-180) via suppression of inflammation and
cell proliferation by regulating PI3K/AKT/mTOR signaling pathway.
Environ Toxicol. 36:1841–1847. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian
Y, Wu D, Zhao Y, Zhang Y, Chen X, et al: Berberine binds RXRα to
suppress β-catenin signaling in colon cancer cells. Oncogene.
36:6906–6918. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Liu Y, Liu X, Zhang N, Yin M, Dong J, Zeng
Q, Mao G, Song D, Liu L and Deng H: Berberine diminishes cancer
cell PD-L1 expression and facilitates antitumor immunity via
inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B.
10:2299–2312. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ham SW, Kim JK, Jeon HY, Kim EJ, Jin X,
Eun K, Park CG, Lee SY, Seo S, Kim JY, et al: Korean Red ginseng
extract inhibits glioblastoma propagation by blocking the Wnt
signaling pathway. J Ethnopharmacol. 236:393–400. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Kim D, Park M, Haleem I, Lee Y, Koo J, Na
YC, Song G and Lee J: Natural product ginsenoside
20(S)-25-Methoxyl-Dammarane-3β, 12β, 20-Triol in cancer treatment:
A review of the pharmacological mechanisms and pharmacokinetics.
Front Pharmacol. 11:5212020. View Article : Google Scholar
|
|
157
|
Yuan Y, Wang J, Xu M, Zhang Y, Wang Z,
Liang L and Sun P: 20(S)-ginsenoside Rh2 as agent for the treatment
of LMN-CRC via regulating epithelial-mesenchymal transition. Biosci
Rep. 40:BSR201915072020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Hashemi F, Zarrabi A, Zabolian A, Saleki
H, Farahani MV, Sharifzadeh SO, Ghahremaniyeh Z, Bejandi AK,
Hushmandi K, Ashrafizadeh M and Khan H: Novel strategy in breast
cancer therapy: Revealing the bright side of ginsenosides. Curr Mol
Pharmacol. 14:1093–1111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Sui H, Zhao J, Zhou L, Wen H, Deng W, Li
C, Ji Q, Liu X, Feng Y, Chai N, et al: Tanshinone IIA inhibits
β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in
normoxic and HIF-1α in hypoxic microenvironments in human
colorectal cancer. Cancer Lett. 403:86–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Li H, Jeong JH, Kwon SW, Lee SK, Lee HJ
and Ryu JH: Z-Aj oene Inhibits Growth of Colon Cancer by Promotion
of CK1α Dependent β-Catenin Phosphorylation. Molecules. 25:7032020.
View Article : Google Scholar
|
|
161
|
Zhu ML, Zheng Z, Lou EZ, Zhao KT, He SY
and Chen JY: Anti-gastric cancer effects of Z Ajoene and its
molecular mechanisms. Zhongguo Ying Yong Sheng Li Xue Za Zhi.
37:514–519. 2021.In Chinese. PubMed/NCBI
|
|
162
|
Li N, Zeng A, Wang Q, Chen M, Zhu S and
Song L: Regulatory function of DNA methylation mediated lncRNAs in
gastric cancer. Cancer Cell Int. 22:2272022. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu
J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its
derivatives can significantly inhibit lung tumorigenesis and tumor
metastasis through Wnt/β-catenin signaling. Oncotarget.
7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wang CZ, Wan C, Luo Y, Zhang CF, Zhang QH,
Chen L, Liu Z, Wang DH, Lager M, Li CH, et al: Effects of
dihydroartemisinin, a metabolite of artemisinin, on colon cancer
chemoprevention and adaptive immune regulation. Mol Biol Rep.
49:2695–2709. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Gong RH, Yang DJ, Kwan HY, Lyu AP, Chen GQ
and Bian ZX: Cell death mechanisms induced by synergistic effects
of halofuginone and artemisinin in colorectal cancer cells. Int J
Med Sci. 19:175–185. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Wen SY, Chen YY, Deng CM, Zhang CQ and
Jiang MM: Nerigoside suppresses colorectal cancer cell growth and
metastatic potential through inhibition of ERK/GSK3β/β-catenin
signaling pathway. Phytomedicine. 57:352–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Yang D, Zhang X, Zhang W and Rengarajan T:
Vicenin-2 inhibits Wnt/β-catenin signaling and induces apoptosis in
HT-29 human colon cancer cell line. Drug Des Devel Ther.
12:1303–1310. 2018. View Article : Google Scholar :
|
|
168
|
Yang MH, Ha IJ, Lee SG, Lee J, Um JY and
Ahn KS: Ginkgolide C promotes apoptosis and abrogates metastasis of
colorectal carcinoma cells by targeting Wnt/β-catenin signaling
pathway. IUBMB Life. 73:1222–1234. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Pashirzad M, Johnston TP and Sahebkar A:
Therapeutic effects of polyphenols on the treatment of colorectal
cancer by regulating Wnt β-Catenin signaling pathway. J Oncol.
2021:36195102021. View Article : Google Scholar
|
|
170
|
Howells LM, Berry DP, Elliott PJ, Jacobson
EW, Hoffmann E, Hegarty B, Brown K, Steward WP and Gescher AJ:
Phase I randomized, double-blind pilot study of micronized
resveratrol (SRT501) in patients with hepatic metastases-safety,
pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila).
4:1419–1425. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Reabroi S, Chairoungdua A, Saeeng R,
Kasemsuk T, Saengsawang W, Zhu W and Piyachaturawat P: A silyl
andrographolide analogue suppresses Wnt/β-catenin signaling pathway
in colon cancer. Biomed Pharmacother. 101:414–421. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Takahashi K, Kikuchi H, Nguyen VH, Oshima
Y, Ishigaki H, Nakajima-Shimada J and Kubohara Y: Biological
activities of novel derivatives of differentiation-inducing factor
3 from dictyostelium discoideum. Biol Pharm Bull. 40:1941–1947.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Totsuka K, Makioka Y, Iizumi K, Takahashi
K, Oshima Y, Kikuchi H and Kubohara Y: Halogen-Substituted
derivatives of dictyostelium differentiation-inducing factor-1
suppress serum-induced cell migration of human breast cancer
MDA-MB-231 cells in vitro. Biomolecules. 9:2562019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Efe Ertürk N and Taşcı S: The effects of
peppermint oil on nausea, vomiting and retching in cancer patients
undergoing chemotherapy: An open label quasi-randomized controlled
pilot study. Complement Ther Med. 56:1025872021. View Article : Google Scholar
|
|
175
|
Li X, Bai B, Liu L, Ma P, Kong L, Yan J,
Zhang J, Ye Z, Zhou H, Mao B, et al: Novel β-carbolines against
colorectal cancer cell growth via inhibition of Wnt/β-catenin
signaling. Cell Death Discov. 1:150332015. View Article : Google Scholar
|
|
176
|
Cha PH, Hwang JH, Kwak DK, Koh E, Kim KS
and Choi KY: APC loss induces Warburg effect via increased PKM2
transcription in colorectal cancer. Br J Cancer. 124:634–644. 2021.
View Article : Google Scholar :
|
|
177
|
Ruan Z, Liang M, Lai M, Shang L, Deng X
and Su X: KYA1797K down-regulates PD-L1 in colon cancer stem cells
to block immune evasion by suppressing the β-catenin/STT3 signaling
pathway. Int Immunopharmacol. 78:1060032020. View Article : Google Scholar
|
|
178
|
Cho YH, Ro EJ, Yoon JS, Kwak DK, Cho J,
Kang DW, Lee HY and Choi KY: Small molecule-induced simultaneous
destabilization of β-catenin and RAS is an effective molecular
strategy to suppress stemness of colorectal cancer cells. Cell
Commun Signal. 18:382020. View Article : Google Scholar
|
|
179
|
Savvidou I, Khong T, Cuddihy A, McLean C,
Horrigan S and Spencer A: β-Catenin Inhibitor BC2059 Is efficacious
as monotherapy or in combination with proteasome inhibitor
bortezomib in multiple myeloma. Mol Cancer Ther. 16:1765–1778.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Savvidou I, Khong T, Whish S, Carmichael
I, Sepehrizadeh T, Mithraprabhu S, Horrigan SK, de Veer M and
Spencer A: Combination of histone deacetylase inhibitor
panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059)
exerts significant anti-myeloma activity both in vitro and in vivo.
Cancers (Basel). 14:8402022. View Article : Google Scholar
|
|
181
|
Choi JH, Jang TY, Jeon SE, Kim JH, Lee CJ,
Yun HJ, Jung JY, Park SY and Nam JS: The small-molecule Wnt
Inhibitor ICG-001 efficiently inhibits colorectal cancer stemness
and metastasis by suppressing MEIS1 Expression. Int J Mol Sci.
22:134132021. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Yang D, Li Q, Shang R, Yao L, Wu L, Zhang
M, Zhang L, Xu M, Lu Z, Zhou J, et al: WNT4 secreted by tumor
tissues promotes tumor progression in colorectal cancer by
activation of the Wnt/β-catenin signalling pathway. J Exp Clin
Cancer Res. 39:2512020. View Article : Google Scholar
|
|
183
|
Song Q, Han Z, Wu X, Wang Y, Zhou L, Yang
L, Liu N, Sui H, Cai J, Ji Q and Li Q: β-Arrestin1 promotes
colorectal cancer metastasis through GSK-3β/β-Catenin
signaling-mediated epithelial-to-mesenchymal transition. Front Cell
Dev Biol. 9:6500672021. View Article : Google Scholar
|
|
184
|
Li B, Orton D, Neitzel LR, Astudillo L,
Shen C, Long J, Chen X, Kirkbride KC, Doundoulakis T, Guerra ML, et
al: Differential abundance of CK1α provides selectivity for
pharmacological CK1α activators to target WNT-dependent tumors. Sci
Signal. 10:eaak99162017. View Article : Google Scholar
|
|
185
|
Zheng W, Hu J, Lv Y, Bai B, Shan L, Chen
K, Dai S and Zhu H: Pyrvinium pamoate inhibits cell proliferation
through ROS-mediated AKT-dependent signaling pathway in colorectal
cancer. Med Oncol. 38:212021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Yang W, Li Y, Ai Y, Obianom ON, Guo D,
Yang H, Sakamuru S, Xia M, Shu Y and Xue F: Pyrazole-4-Carboxamide
(YW2065): A therapeutic candidate for colorectal cancer via dual
activities of Wnt/β-Catenin signaling inhibition and AMP-Activated
protein kinase (AMPK) activation. J Med Chem. 62:11151–11164. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Song P, Feng L, Li J, Dai D, Zhu L, Wang
C, Li J, Li L, Zhou Q, Shi R, et al: β-catenin represses miR455-3p
to stimulate m6A modification of HSF1 mRNA and promote its
translation in colorectal cancer. Mol Cancer. 19:1292019.
View Article : Google Scholar
|
|
188
|
Wang Z, Zhou L, Wang Y, Peng Q, Li H,
Zhang X, Su Z, Song J, Sun Q, Sayed S, et al: The CK1δ/ε-AES axis
regulates tumorigenesis and metastasis in colorectal cancer.
Theranostics. 11:4421–4435. 2021. View Article : Google Scholar :
|
|
189
|
Li Y, Rogoff HA, Keates S, Gao Y,
Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB and Li CJ:
Suppression of cancer relapse and metastasis by inhibiting cancer
stemness. Proc Natl Acad Sci USA. 112:1839–1844. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: BBI608 inhibits cancer stemness
and reverses cisplatin resistance in NSCLC. Cancer Lett.
428:117–126. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Han D, Yu T, Dong N, Wang B, Sun F and
Jiang D: Napabucasin, a novel STAT3 inhibitor suppresses
proliferation, invasion and stemness of glioblastoma cells. J Exp
Clin Cancer Res. 38:2892019. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Beyreis M, Gaisberger M, Jakab M,
Neureiter D, Helm K, Ritter M, Kiesslich T and Mayr C: The cancer
stem cell inhibitor napabucasin (BBI608) shows general cytotoxicity
in biliary tract cancer cells and reduces cancer stem cell
characteristics. Cancers (Basel). 11:2762019. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Jonker DJ, Nott L, Yoshino T, Gill S,
Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, et al:
Napabucasin versus placebo in refractory advanced colorectal
cancer: A randomised phase 3 trial. Lancet Gastroenterol Hepatol.
3:263–270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Tam BY, Chiu K, Chung H, Bossard C, Nguyen
JD, Creger E, Eastman BW, Mak CC, Ibanez M, Ghias A, et al: The CLK
inhibitor SM08502 induces anti-tumor activity and reduces Wnt
pathway gene expression in gastrointestinal cancer models. Cancer
Lett. 473:186–197. 2020. View Article : Google Scholar
|
|
195
|
Kajino-Sakamoto R, Fujishita T, Taketo MM
and Aoki M: Synthetic lethality between MyD88 loss and mutations in
Wnt/β-catenin pathway in intestinal tumor epithelial cells.
Oncogene. 40:408–420. 2021. View Article : Google Scholar
|
|
196
|
Chen Y, Rao X, Huang K, Jiang X, Wang H
and Teng L: FH535 inhibits proliferation and motility of colon
cancer cells by targeting wnt/β-catenin signaling pathway. J
Cancer. 8:3142–3153. 2017. View Article : Google Scholar :
|
|
197
|
Tu X, Hong D, Jiang Y, Lou Z, Wang K,
Jiang Y and Jin L: FH535 inhibits proliferation and migration of
colorectal cancer cells by regulating CyclinA2 and Claudin1 gene
expression. Gene. 690:48–56. 2019. View Article : Google Scholar
|
|
198
|
Hua F, Shang S, Yang YW, Zhang HZ, Xu TL,
Yu JJ, Zhou DD, Cui B, Li K, Lv XX, et al: TRIB3 Interacts With
β-Catenin and TCF4 to increase stem cell features of colorectal
cancer stem cells and tumorigenesis. Gastroenterology.
156:708–721.e15. 2019. View Article : Google Scholar
|
|
199
|
Shang S, Yang YW, Chen F, Yu L, Shen SH,
Li K, Cui B, Lv XX, Zhang C, Yang C, et al: TRIB3 reduces CD8(+) T
cell infiltration and induces immune evasion by repressing the
STAT1-CXCL10 axis in colorectal cancer. Sci Transl Med.
14:eabf09922022. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Cai X, Wei B, Li L, Chen X, Yang J, Li X,
Jiang X, Lv M, Li M, Lin Y, et al: Therapeutic potential of
apatinib against colorectal cancer by inhibiting VEGFR2-Mediated
Angiogenesis and β-Catenin Signaling. Onco Targets Ther.
13:11031–11044. 2020. View Article : Google Scholar :
|
|
201
|
Or CR, Huang CW and Chang CC, Lai YC, Chen
YJ and Chang CC: Obatoclax, a Pan-BCL-2 inhibitor, downregulates
survivin to induce apoptosis in human colorectal carcinoma cells
via suppressing WNT/β-catenin Signaling. Int J Mol Sci.
21:17732020. View Article : Google Scholar
|
|
202
|
Gan T, Stevens AT, Xiong X, Wen YA, Farmer
TN, Li AT, Stevens PD, Golshani S, Weiss HL, Evers BM and Gao T:
Inhibition of protein tyrosine phosphatase receptor type F
suppresses Wnt signaling in colorectal cancer. Oncogene.
39:6789–6801. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Song W, Ma J, Lei B, Yuan X, Cheng B, Yang
H, Wang M, Feng Z and Wang L: Sine oculis homeobox 1 promotes
proliferation and migration of human colorectal cancer cells
through activation of Wnt/β-catenin signaling. Cancer Sci.
110:608–616. 2019. View Article : Google Scholar :
|
|
204
|
Lepore Signorile M, Grossi V, Di Franco S,
Forte G, Disciglio V, Fasano C, Disciglio V, Fasano C, Sanese P, De
Marco K, et al: Pharmacological targeting of the novel β-catenin
chromatin-associated kinase p38α in colorectal cancer stem cell
tumorspheres and organoids. Cell Death Dis. 12:3162021. View Article : Google Scholar
|
|
205
|
Sheng YH, Wong KY, Seim I, Wang R, He Y,
Wu A, Patrick M, Lourie R, Schreiber V, Giri R, et al: MUC13
promotes the development of colitis-associated colorectal tumors
via β-catenin activity. Oncogene. 38:7294–7310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Li Q, Wang G, Tao J and Chen W: RNF6
promotes colorectal cancer invasion and migration via the
Wnt/β-catenin pathway by inhibiting GSK3β activity. Pathol Res
Pract. 225:1535452021. View Article : Google Scholar
|
|
207
|
Peng W, Zhang H, Tan S, Li Y, Zhou Y, Wang
L, Liu C, Li Q, Cen X, Yang S and Zhao Y: Synergistic antitumor
effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in
colorectal cancer. Ther Adv Med Oncol. 12:17588359209374282020.
View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Zhu Y, Gu L, Lin X, Zhang J, Tang Y, Zhou
X, Lu B, Lin X, Liu C, Prochownik EV and Li Y: Ceramide-mediated
gut dysbiosis enhances cholesterol esterification and promotes
colorectal tumorigenesis in mice. JCI Insight. 7:e1506072022.
View Article : Google Scholar :
|
|
209
|
Chen Z, Wu J, Liu B, Zhang G, Wang Z,
Zhang L, Wang K, Fan Z and Zhu P: Identification of cis-HOX-HOXC10
axis as a therapeutic target for colorectal tumor-initiating cells
without APC mutations. Cell Rep. 36:1094312021. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Wang C, Dai J, Sun Z, Shi C, Cao H, Chen
X, Gu S, Li Z, Qian W and Han X: Targeted inhibition of disheveled
PDZ domain via NSC668036 depresses fibrotic process. Exp Cell Res.
331:115–122. 2015. View Article : Google Scholar
|
|
211
|
Pradhan TR and Mohapatra DK: A synthetic
study toward the core structure of (-)-apicularen A. Org Biomol
Chem. 16:8810–8818. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Mauvezin C and Neufeld TP: Bafilomycin A1
disrupts autophagic flux by inhibiting both V-ATPase-dependent
acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome
fusion. Autophagy. 11:1437–1438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Wang J, Mook RA Jr, Ren XR, Zhang Q, Jing
G, Lu M, Spasojevic I, Lyerly HK, Hsu D and Chen W: Identification
of DK419, a potent inhibitor of Wnt/β-catenin signaling and
colorectal cancer growth. Bioorg Med Chem. 26:5435–5442. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
214
|
An T, Gong Y, Li X, Kong L, Ma P, Gong L,
Zhu H, Yu C, Liu J, Zhou H, et al: USP7 inhibitor P5091 inhibits
Wnt signaling and colorectal tumor growth. Biochem Pharmacol.
131:29–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Kumar B, Ahmad R, Sharma S, Gowrikumar S,
Primeaux M, Rana S, Natarajan A, Oupicky D, Hopkins CR, Dhawan P
and Singh AB: PIK3C3 inhibition promotes sensitivity to colon
cancer therapy by inhibiting cancer stem cells. Cancers (Basel).
13:21682021. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Ye GD, Sun GB, Jiao P, Chen C, Liu QF,
Huang XL, Zhang R, Cai WY, Li SN, Wu JF, et al: OVOL2, an inhibitor
of WNT signaling, reduces invasive activities of human and mouse
cancer cells and is down-regulated in human colorectal tumors.
Gastroenterology. 150:659–671.e16. 2016. View Article : Google Scholar
|
|
217
|
Monin MB, Krause P, Stelling R, Bocuk D,
Niebert S, Klemm F, Pukrop T and Koenig S: The anthelmintic
niclosamide inhibits colorectal cancer cell lines via modulation of
the canonical and noncanonical Wnt signaling pathway. J Surg Res.
203:193–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Ren Y, Tao J, Jiang Z, Guo D and Tang J:
Pimozide suppresses colorectal cancer via inhibition of
Wnt/β-catenin signaling pathway. Life Sci. 209:267–273. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Fako V, Yu Z, Henrich CJ, Ransom T, Budhu
AS and Wang XW: Inhibition of wnt/β-catenin signaling in
hepatocellular carcinoma by an antipsychotic drug pimozide. Int J
Biol Sci. 12:768–775. 2016. View Article : Google Scholar :
|
|
220
|
Al-Dali AM, Weiher H and Schmidt-Wolf IGH:
Utilizing ethacrynic acid and ciclopirox olamine in liver cancer.
Oncol Lett. 16:6854–6860. 2018.PubMed/NCBI
|
|
221
|
Liu Q, Zeng A, Liu Z, Wu C and Song L:
Liver organoids: From fabrication to application in liver diseases.
Front Physiol. 13:9562442022. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Caspi M, Wittenstein A, Kazelnik M,
Shor-Nareznoy Y and Rosin-Arbesfeld R: Therapeutic targeting of the
oncogenic Wnt signaling pathway for treating colorectal cancer and
other colonic disorders. Adv Drug Deliv Rev. 169:118–136. 2021.
View Article : Google Scholar
|
